The current price of SXTP is $0.9164 — it has decreased by 4.17% since the previous close. Data as of Nov 5, 2026.
SXTP is down 2.88% over the past week, down 36.36% over the past month and down 82.38% over the past year. The price is below its 200-day moving average of $1.76.
Of the 2 analysts covering 60 Degrees Pharmaceuticals, Inc., 1 rates it a buy and 1 rates it a hold. The overall consensus is neutral. Analyst ratings are opinions and do not guarantee future performance.
60 Degrees Pharmaceuticals, Inc. has a market capitalization of $3.22M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, 60 Degrees Pharmaceuticals, Inc. posted a loss of $0.90 per share against an estimate of -$0.735, missing expectations by 22.45%. Upcoming reports are listed in the earnings calendar.
60 Degrees Pharmaceuticals, Inc. reported revenue of $207.9K in its most recent quarter, which has decreased by 31.84% compared with the same quarter a year earlier. Analysts had expected $185K.
Companies most comparable to 60 Degrees Pharmaceuticals, Inc. include Biodexa Pharmaceuticals Plc, Kazia Therapeutics Ltd ADR, Soligenix, Inc., CNS Pharmaceuticals, Inc. and GRI Bio, Inc.
In the latest trading session SXTP moved between $0.86 and $0.9164, a range of 6.15% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of 60 Degrees Pharmaceuticals, Inc. shows a sell rating today and a sell rating on the weekly timeframe. Technical ratings are indicators, not investment advice.
Over the past 52 weeks SXTP has traded between $0.588 and $8.62. The current price is 89.37% below its 52-week high.
Figures as of Nov 5, 2026. This information is provided for general purposes only and is not investment advice.